TheraBionic P1 Device

What is the TheraBionic P1 device?

The Barbara Ann Karmanos Cancer Institute is the first to offer the new patented, FDA-approved TheraBionic P1 device to treat eligible advanced hepatocellular carcinoma (HCC - liver cancer) in eligible patients. The TheraBionic P1 device is a small portable device that delivers radiofrequency electromagnetic fields throughout the entire body. The radiofrequency electromagnetic fields are tumor-specific and block the growth of tumor cells without affecting normal cells. For example, liver cancer frequencies are solely effective in the treatment of liver cancer.

How does the TheraBionic P1 device work?

The TheraBionic P1’s tumor-specific frequencies are dispensed through a small metal spoon. This spoon-shaped antenna is placed on the tongue and distributes radiofrequencies throughout the entire body. The metal spoon is connected to the P1 device, which is slightly larger than a cell phone, making it portable and convenient for the recommended one-hour treatment time. Treatment with the TheraBionic P1 device should be administered three times a day and can be conveniently delivered at home, or even on the go.

What are the benefits of the TheraBionic P1 device?

For more than two decades, multiple studies have shown that patients utilizing the TheraBionic P1 device did not experience the same debilitating side effects associated with other cancer-fighting therapies. Patients in these studies did not experience diarrhea, irritation of the palms and soles, or appetite loss. The TheraBionic P1 device can provide the following benefits:

• Treatment efficacy
• Minimizing adverse events
• Symptomatic benefit
• Convenience of treatment

In patients with advanced liver cancer whose other cancer therapies failed, 10% of patients who utilized the TheraBionic P1 device were reported to have tumor shrinkage and 50% of patients had a stable disease that lasted more than six months. In patients with liver cancer, survival rates increased by 34% using the TheraBionic P1 therapy.

Watch TheraBionic P1 Device Instructional Videos

Who is eligible for the TheraBionic P1 device?

The TheraBionic P1 device is FDA-approved for the treatment of HCC, the most common form of liver cancer. Patients 18 and older with advanced HCC who have failed first- and second-line therapies are eligible for treatment with the TheraBionic P1 device.

More Information

To see if the TheraBionic P1 device is right for you, please choose from the options below:

• Call 1-800-KARMANOS (1-800-527-6266)
• Request an Appointment Online – a Karmanos representative will contact you within 24 hours of your request, Monday through Friday.
• Refer a Patient

Learn more about the Gastrointestinal Oncology Team at Karmanos